GILEAD SCIENCES Reports Q3 Earnings for FY2023
November 23, 2023
🌥️Earnings Overview
For the third quarter of FY2023, GILEAD SCIENCES ($NASDAQ:GILD) reported total revenue of USD 7.0 billion, a slight 0.1% increase from Q3 of FY2022. Net income also rose 21.8%, coming in at USD 2.2 billion when compared to the same quarter in the prior year. The period ending was September 30 2023.
Market Price
On Tuesday, GILEAD SCIENCES reported its earnings for Q3 in the fiscal year 2023. The stock opened at $81.1 and closed at $80.6, down by 0.7% from the previous closing price of 81.1. The stock has experienced a decline in the quarter due to a lack of new product launches.
Despite this, GILEAD SCIENCES showed strong sales from existing products and a record high in its research and development expenses. The company is confident that its new product launches planned for the upcoming quarters will help to improve their stock performance and overall financial picture. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Gilead Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 27.39k | 5.88k | 32.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Gilead Sciences. More…
| Operations | Investing | Financing |
| 8.4k | -1.91k | -5.58k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Gilead Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 62.37k | 40.13k | 17.91 |
Key Ratios Snapshot
Some of the financial key ratios for Gilead Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.8% | 43.3% | 29.8% |
| FCF Margin | ROE | ROA |
| 28.7% | 23.5% | 8.2% |
Analysis
GoodWhale has provided an analysis of the fundamentals of GILEAD SCIENCES. After looking at the Star Chart, we concluded that GILEAD SCIENCES is strong in asset, dividend, and profitability, and medium in growth. We also gave GILEAD SCIENCES a health score of 8/10, meaning that the company is capable to sustain future operations in times of crisis. Furthermore, we classified GILEAD SCIENCES as a ‘rhino’, a type of company which has achieved moderate revenue or earnings growth. Given these details, long-term investors who are looking for steady returns may be interested in GILEAD SCIENCES. Moreover, those investors who prioritize safety and stability may also benefit from investing in this company. In essence, GILEAD SCIENCES can provide a reliable income stream for those investors who are looking for it. More…
Peers
In the biopharmaceutical industry, competition is fierce. Among the companies vying for market share are Gilead Sciences Inc, Eli Lilly and Co, Amgen Inc, and SCYNEXIS Inc. All of these companies are working to develop new and innovative treatments for a variety of diseases.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company with a market cap of 316.8 billion as of May 2021. The company has a return on equity of 45.88% and is headquartered in Indianapolis, Indiana. Eli Lilly and Co develops and markets prescription medications and over-the-counter products. The company’s products are available in approximately 120 countries.
– Amgen Inc ($NASDAQ:AMGN)
Amgen Inc is a biopharmaceutical company with a market cap of 135.3B as of 2022. The company has a return on equity of 460.37%. Amgen Inc is a biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics worldwide. The company offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and nephrology.
– SCYNEXIS Inc ($NASDAQ:SCYX)
SCYNEXIS Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. The company’s lead product, SCY-078, is an oral and intravenous antifungal agent in Phase 3 clinical development for the treatment of serious and life-threatening invasive fungal infections. SCYNEXIS Inc. was founded by Peter R. Lupton, David P. Lupton and George W. Schmidt in December 1997 and is headquartered in Durham, NC.
Summary
GILEAD SCIENCES experienced positive growth in the third quarter of FY2023. Total revenue increased marginally by 0.1% year-over-year to USD 7.0 billion, while net income increased significantly by 21.8% year-over-year to USD 2.2 billion. This strong financial performance indicates that the company is performing well and is a promising investment opportunity. GILEAD SCIENCES is a strong company with a solid financial position, making it a good option for long-term investments.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
